News Release

Emerging vaccine nanotechnology

Peer-Reviewed Publication

Compuscript Ltd

In this new article publication from Acta Pharmaceutica Sinica B, authors Chan Feng, Yongjiang Li, Bijan Emiliano Ferdows and colleagues from Zhejiang University School of Medicine, Hangzhou, China, Harvard Medical School, Boston, MA, USA, Zhejiang University, Hangzhou, China and Central South University, Changsha, China discuss emerging vaccine nanotechnology.

Looking retrospectively at the development of humanity, vaccination is an unprecedented medical landmark that saves lives by harnessing the human immune system. During the ongoing coronavirus disease 2019 (COVID-19) pandemic, vaccination is still the most effective defense modality.

 

The successful clinical application of the lipid nanoparticle-based Pfizer/BioNTech and Moderna mRNA COVID-19 vaccines highlights promising future of nanotechnology in vaccine development. Compared with conventional vaccines, nanovaccines are supposed to have advantages in lymph node accumulation, antigen assembly, and antigen presentation; they also have, unique pathogen biomimicry properties because of well-organized combination of multiple immune factors. Beyond infectious diseases, vaccine nanotechnology also exhibits considerable potential for cancer treatment. The ultimate goal of cancer vaccines is to fully mobilize the potency of the immune system as a living therapeutic to recognize tumor antigens and eliminate tumor cells, and nanotechnologies have the requisite properties to realize this goal.

 

In this review, the authors summarize the recent advances in vaccine nanotechnology from infectious disease prevention to cancer immunotherapy and highlight the different types of materials, mechanisms, administration methods, as well as future perspectives.

 

Article reference: Chan Feng, Yongjiang Li, Bijan Emiliano Ferdows, Dylan Neal Patel, Jiang Ouyang, Zhongmin Tang, Na Kong, Enguo Chen, Wei Tao, Emerging vaccine nanotechnology: From defense against infection to sniping cancer, Acta Pharmaceutica Sinica B, Volume 12, Issue 5,

2022, Pages 2206-2223, ISSN 2211-3835, https://doi.org/10.1016/j.apsb.2021.12.021.

Keywords: Vaccine; Nanotechnology; Infection; Cancer; Nanovaccines; Vaccination; Diseases prevention; Immunotherapy

Graphical Abstract: available at https://ars.els-cdn.com/content/image/1-s2.0-S2211383521004937-ga1.jpg

In this review, the authors summarize the recent advances in the application of vaccine nanotechnology for infectious disease prevention and cancer immunotherapy, involving the contribution of materials, mechanisms, and administration methods.

# # # # # #

The Journal of the Institute of Materia Medica, the Chinese Academy of Medical Sciences and the Chinese Pharmaceutical Association.

For more information please visit https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/

Editorial Board: https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/editorial-board

 

APSB is available on ScienceDirect (https://www.sciencedirect.com/journal/acta-pharmaceutica-sinica-b).

 

Submissions to APSB may be made using Editorial Manager® (https://www.editorialmanager.com/apsb/default.aspx).

 

CiteScore: 12.5

Impact Factor: 11.614

JIF without self-citation: 10.746

 

ISSN 2211-3835

 # # # # #

 


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.